A Phase 2 Study of Oxaliplatin Combined With Continuous Infusion Topotecan for Patients With Previously Treated Ovarian Cancer

Abstract

Background Phase II trials suggest that prolonged intravenous (IV) infusion of the topoisomerase-1 inhibitor topotecan may be less toxic than when given by standard IV bolus 5-day administration. Oxaliplatin exhibits efficacy in platinum- pretreated disease and shows preclinical synergy with topoisomerase-I inhibitors. We sought to determine the efficacy and safety of oxaliplatin plus infusion topotecan in recurrent platinum-pretreated ovarian cancer. Methods Patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancers previously treated with 1–2 prior regimens including a platinum and taxane received oxaliplatin (85 mg/m2 day 1, 15) and topotecan (0.4 mg/m2/day) by continuous IV infusion over 14 days every 4 weeks. The primary objective of the trial was to estimate the objective response rate in platinum-resistant disease (stratum I) and in platinum-sensitive disease (stratum II). Toxicities were assessed in all patients. Results Thirty-eight patients received 144 cycles of therapy (median 4, range 1–6). The most common grade 3/4 toxicities included thrombocytopenia (37% grade 3, 19% grade 4), neutropenia (37% grade 3, 11% grade 4) and anemia (15% grade 3). Response occurred in 4 of 19 patients in stratum I (21%, 95% confidence intervals [CI] 6%, 46%) and 9 of 19 patients in stratum II (47%, 95% CI 24%, 71%). Three in each stratum had lengthy complete responses. Conclusions Biweekly oxaliplatin plus a 14-day continuous IV infusion of topotecan, given monthly, is an active regimen in platinum-pretreated ovarian cancer and merits additional evaluation.

Dual-Targeting Nanoparticles for In Vivo Delivery of Suicide Genes to Chemotherapy-Resistant Ovarian Cancer Cells

“…This approach, although widely utilized in clinical practice for the i.v. delivery of therapeutics in patients(29, 30), is challenging in preclinical models and has been successful only for sub-cutaneous or intraperitoneal delivery of drugs in mice(31, 32). Accordingly, we chose to inject nanoparticles intraperitoneally (IP).…”

Novel treatment of refractory / recurrent pulmonary hepatoblastoma

“…16,17 Because of this, some institutions choose oxaliplatin combined with topotecan as a second-line treatment therapy. 18,19 In our institution, several different kinds of anticancer agents had been tried before, and OVT would be applied after weighing against the chemotherapy-related side effects and the chance of survival, as the critical point in curing these patients would be the responsiveness of lung metastases. Obviously, OVT alone is not sufficient.…”

Effect of Pterostilbene, a Natural Derivative of Resveratrol, in the Treatment of Colorectal Cancer through Top1/Tdp1-Mediated DNA Repair Pathway

“…In addition, in terms of administration, these drugs also have some shortcomings. For example, some drugs have so low solubility that the intravenous dripping time has to be extended to achieve the maximum therapeutic effect [7][8][9][10][11]. At physiological pH, CPT is easily hydrolyzed into CPT carboxylate, seriously affecting its efficacy [12].…”